Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported multiple equity transactions. On March 2, 2026, he exercised stock options for 5,125 shares of common stock at a stated price of $9.5900 per share and received the underlying shares. That same day he sold a total of 3,000 shares of common stock in open‑market transactions in three blocks at weighted average prices of $198.8338, $200.1073, and $200.9679 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 26, 2024, leaving 150,023 shares held directly after the reported sales. On February 27, 2026, he also received a grant of 10,051 restricted stock units, each representing one share of common stock, which vest over four years, with 25% vesting on March 1, 2027 and the rest vesting in 12 equal quarterly installments thereafter.
Rabinowitz Matthew reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. executive chairman Matthew Rabinowitz received an equity award of 29,920 restricted stock units (RSUs). The RSUs were granted on February 27, 2026 at no cash cost and each RSU represents one share of common stock. Vesting begins March 1, 2027, when 25% vests, with the remainder vesting in 12 equal quarterly installments over the following three years.
RABINOWITZ DANIEL reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, received a grant of 12,272 restricted stock units (RSUs) of common stock on February 27, 2026. These RSUs vest over four years, with 25% vesting on March 1, 2027 and the remainder in 12 equal quarterly installments. Each RSU represents the right to receive one share of Natera common stock, bringing his directly owned total to 236,085 shares after the award.
Fesko John reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. reported that President and Chief Business Officer John Fesko received a grant of 10,051 restricted stock units (RSUs) on common stock. These RSUs vest over four years, with 25% vesting on March 1, 2027 and the rest in 12 equal quarterly installments. After this award, Fesko holds 188,132 shares of common stock directly.
Natera, Inc. reported that Chief Financial Officer Michael Burkes Brophy received a grant of 10,051 Restricted Stock Units (RSUs) of common stock at no cost. The RSUs vest over four years, with 25% vesting on March 1, 2027 and the remainder in 12 equal quarterly installments. Each RSU converts into one share of common stock when it vests. Following this award, Brophy holds 62,171 shares of Natera common stock directly.
Steven L. Chapman reported multiple sales of Common stock of NTRA via Form 144. The filing lists individual dispositions on 01/02/2026, 01/20/2026, 01/21/2026, 01/27/2026, 01/28/2026, and 02/02/2026, including a sale of 85,299 shares on 02/02/2026 for $19,679,798.82. The transactions are reported through Morgan Stanley Smith Barney LLC as broker.
Solomon Moshkevich reported a proposed sale of 3,000 performance shares under a Form 144 notice. The filing lists multiple recent dispositions of Common stock between 12/12/2025 and 02/02/2026, including transactions of 23,205, 4,692, and other lot sizes with dollar amounts shown.
The notice names Morgan Stanley Smith Barney LLC as the broker and identifies the securities class as Common. Timing and cash‑flow treatment for the proposed 3,000 performance shares are tied to the Form 144 filing process.
Natera, Inc. reports strong 2025 growth with total revenues of $2.31 billion, up from $1.70 billion in 2024, driven mainly by higher volumes and pricing in its Panorama, Horizon and Signatera testing businesses. The company processed about 3.53 million tests in 2025, up from 3.06 million in 2024, including a jump in oncology units from roughly 528,200 to 800,800.
Despite growth, Natera remained unprofitable, posting a 2025 net loss of $208.2 million versus a $190.4 million loss in 2024, with higher research and development and selling, general and administrative expenses. However, operating cash flow improved to $215.3 million, and the company ended 2025 with $1.08 billion in cash, cash equivalents and restricted cash and $80.3 million drawn on its UBS credit line. Natera also completed the acquisition of Foresight Diagnostics, recording a $335.3 million developed technology intangible asset that it values using discounted future cash flows.
Natera, Inc. reported strong growth for the fourth quarter and full year 2025. Total revenue reached $665.5 million in Q4 2025, up 39.8% from Q4 2024, and $2,306.1 million for 2025, a 35.9% increase over 2024, driven mainly by higher product revenues and better pricing.
The company processed about 3.53 million tests in 2025, with oncology test volumes rising 51.6% to roughly 800,800. Gross margin improved to 64.7% for 2025, up from 60.3% in 2024, as scale and cost efficiencies took hold.
Natera achieved positive cash inflow of approximately $107.6 million in 2025, while still posting a net loss of $208.2 million, or ($1.52) per diluted share. Management guides 2026 revenue to $2.62–$2.70 billion with gross margin of 63%–65% and expects positive net cash inflow.
T. Rowe Price Associates, Inc. reported beneficial ownership of 10,872,702 shares of Natera Inc. common stock, representing 7.8% of the class as of 12/31/2025. It has sole voting power over 10,475,212 shares and sole dispositive power over 10,871,989 shares.
The firm states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Natera. It also disclaims being the beneficial owner of the securities, despite filing this Schedule 13G/A amendment.